Phase I/II, open-label, Multi-center, Two part dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy study of AZD4877 in patients with acute myelogenous leukemia (AML)
Study identifier:D2782C00007
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Terminated/Withdrawn
Official Title
A Phase I/II, Open-Label, Multi-Center, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD4877 Administered on Days 1, 2 and 3 in Adult Patients with Recurrent or Refractory Acute Myelogenous Leukemia (AML) Excluding Promyelocytic Leukemia
Medical condition
acute myelogenous leukemia
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD4877
Sex
All
Actual Enrollment
47
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Jul 2007
Primary Completion Date: -
Study Completion Date: 01 Jul 2009
Study design
Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Gregory A Curt
AstraZeneca
